Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.

ABSTRACT:

Background & aims

Rectal indomethacin, a nonsteroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials. The European Society for Gastrointestinal Endoscopy guidelines recently recommended prophylactic rectal indomethacin for all patients undergoing ERCP, including those at average risk for pancreatitis. We performed a randomized controlled trail to investigate the efficacy of this approach.

Methods

We performed a prospective, double-blind, placebo-controlled trial of 449 consecutive patients undergoing ERCP at Dartmouth Hitchcock Medical Center, from March 2013 through December 2014. Approximately 70% of the cohort were at average risk for PE

SUBMITTER: Levenick JM 

PROVIDER: S-EPMC4808426 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature